OncoMatch/Clinical Trials/NCT06465316
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Is NCT06465316 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Iberdomide and Teclistamab for recurrent multiple myeloma.
Treatment: Iberdomide · Teclistamab — This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor (bortezomib, carfilzomib, ixazomib)
Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib)
Must have received: immunomodulatory imide drug (thalidomide, lenalidomide, pomalidomide)
Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one immunomodulatory imide drug (ImiD) (e.g., thalidomide, lenalidomide, pomalidomide [POM])
Must have received: anti-CD38 monoclonal antibody (daratumumab, isatuximab)
Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab)
Cannot have received: anti-BCMA directed bispecific antibody
Patients who have had prior anti-BCMA directed bispecific antibody (BsAb) therapy exposure (prior treatment with anti-BCMA directed antibody drug conjugate, anti-BCMA-directed chimeric antigen receptor (CAR) T cell therapy, and prior non-BCMA-targeting BsAb are permitted)
Cannot have received: cereblon E3 ligase modulator (mezigdomide, iberdomide, CFT7455)
Patients who have had prior treatment with a cereblon E3 ligase modulator, including mezigdomide, iberdomide, and CFT7455 (all currently in clinical development)
Cannot have received: allogeneic stem cell transplant
Patients who received a prior allogeneic SCT. Autologous SCT is allowed
Lab requirements
Blood counts
Hemoglobin ≥ 7.0 g/dL; Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 50,000/mcL (all without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin)
Kidney function
Estimated glomerular filtration rate (eGFR) > 30 mL/min; Spot urine (albumin/creatine ratio) ≤ 500mg/g (56 mg/mmol) OR urine dipstick negative/trace (if > 1+ only eligible if confirmed ≤ 500 mg/g (56 mg/mmol) by albumin/creatinine ratio)
Liver function
Total bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST/ALT ≤ 3 x institutional ULN
Cardiac function
New York Heart Association Functional Classification class II or better
Hemoglobin ≥ 7.0 g/dL... Absolute neutrophil count ≥ 1,000/mcL... Platelets ≥ 50,000/mcL... Total bilirubin ≤ 2 x institutional upper limit of normal (ULN)... AST/ALT ≤ 3 x institutional ULN... Estimated glomerular filtration rate (eGFR) > 30 mL/min... Spot urine (albumin/creatine ratio) ≤ 500mg/g (56 mg/mmol)... New York Heart Association Functional Classification class II or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Kansas Hospital-Westwood Cancer Center · Westwood, Kansas
- Mayo Clinic in Rochester · Rochester, Minnesota
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- University of Oklahoma Health Sciences Center · Oklahoma City, Oklahoma
- VCU Massey Comprehensive Cancer Center · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06465316 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-BCMA directed bispecific antibody, cereblon E3 ligase modulator, allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages